Ciltacabtagene autoleucel (cilta-cel; Carvykti) for multiple myeloma has a new boxed warning for immune effector ...

Common causes of low back pain include muscle strain, trauma, osteoporosis, and autoimmune disorders.

Scientists discovered that inhibiting the enzyme STK17B forces multiple myeloma cells into iron-driven death and makes ...

The U.S. Food and Drug Administration (FDA) has updated the safety labeling for Carvykti, the multiple myeloma therapy ...

While it’s not as well-known as, say, leukemia or melanoma, multiple myeloma is the second most common blood cancer in adults, according to the Cancer Research Institute. “Multiple myeloma is a cancer ...

Iberdomide combined with standard therapies showed a statistically significant improvement in minimal residual disease (MRD) negativity rates, compared with the control arm, in patients with relapsed ...

Researchers at Duke University have shown that blocking an enzyme involved in iron regulation not only kills multiple myeloma cancer cells, but also increases the effectiveness of current therapies ...